G3 Therapeutics is an innovative drug discovery company that combines extensive biological data, artificial intelligence (AI), and machine learning to develop breakthrough therapies. They are a pre-clinical stage biotechnology company focused on developing novel therapeutic approaches for serious diseases that cause significant individual suffering and societal burden. Unlike traditional biopharmaceutical companies, G3 Therapeutics utilizes deep, panomic biological big data and visionary machine learning and AI approaches to analyze and develop their own revelationary therapeutics.

By combining expertise from various disciplines such as genomics, epigenetics, transcriptomics, proteomics, imaging, and AI/ML, G3 Therapeutics provides a unique solution in the field of drug discovery. They rejuvenate the process by combining highly quantitative, deep phenotyping data from humans with comprehensive molecular profiling, unraveling novel biology. G3 Therapeutics anchors their novel therapeutics in human genetic target validation, increasing the odds of a successful launch.

With a team of experienced professionals and advisors, including distinguished drug developers, G3 Therapeutics is at the forefront of developing groundbreaking therapies for serious diseases